Opticron (Sodium Cromoglicate)

Sodium cromoglicate stabilizes mast cells in the ocular tissues, preventing their degranulation and the subsequent release of histamine and other inflammatory mediators. By blocking these pathways, it reduces vascular permeability and the inflammatory response that leads to eye allergy symptoms.

The dosage of Opticron is determined by the prescribing clinician based on the patient’s condition and response. Typically, a few drops are instilled into the affected eye(s) as directed, but the exact regimen should follow the healthcare professional’s instructions.

Safety data for sodium cromoglicate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Opticron.

To order Opticron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Opticron (sodium cromoglicate) is a mast cell stabilizer, whereas many alternative eye drops are antihistamines or corticosteroids. Mast cell stabilizers act upstream by preventing mediator release, offering a preventive approach, while antihistamines provide rapid symptom relief. Choice depends on the clinical scenario and physician preference.

Opticron should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct light and moisture, and avoid freezing. Do not use the product if the solution appears discolored or contains particles.

Opticron is administered as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid to form a pocket, and place the prescribed number of drops into the conjunctival sac. Close the eyes gently for a few seconds and avoid blinking excessively.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, corneal ulceration, persistent eye pain, intra‑ocular inflammation, and significant vision loss. Any sudden worsening of eye symptoms or signs of a severe reaction should prompt immediate medical evaluation.

Opticron should not be used by individuals with a known hypersensitivity to sodium cromoglicate or any excipients in the formulation. It is also contraindicated in patients with active ocular infections unless directed by a physician, and caution is advised for pregnant or breastfeeding women until safety is confirmed.